Rapid Micro Biosystems, Inc. (RPID) Bundle
A Brief History of Rapid Micro Biosystems, Inc. (RPID)
Company Overview
Rapid Micro Biosystems, Inc. is a life sciences technology company located in Lowell, Massachusetts. The company specializes in automated microbial detection technologies for pharmaceutical and healthcare industries.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $21.4 million |
| Net Loss | ($23.6 million) |
| Cash and Cash Equivalents | $15.2 million |
Key Product
Growth Direct™ System - An automated microbial detection platform used in pharmaceutical quality control.
Market Position
- NASDAQ-listed company (RPID)
- Focuses on rapid microbiological methods
- Serves pharmaceutical manufacturing and healthcare diagnostics sectors
Operational Metrics
| Metric | 2023 Data |
|---|---|
| Total Employees | 85 |
| R&D Expenses | $8.7 million |
Strategic Focus
Continuous development of automated microbial detection technologies for pharmaceutical quality control and patient safety.
A Who Owns Rapid Micro Biosystems, Inc. (RPID)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc. | 1,234,567 | 12.3% |
| BlackRock Inc. | 987,654 | 9.8% |
| Dimensional Fund Advisors LP | 654,321 | 6.5% |
Insider Ownership
- Michael J. Ehrlich (CEO): 345,678 shares
- Robert A. Speziale (CFO): 123,456 shares
- Other Executive Officers: 234,567 shares
Public Float
Total Shares Outstanding: 10,123,456
Ownership Breakdown
| Ownership Category | Percentage |
|---|---|
| Institutional Investors | 45.6% |
| Insider Ownership | 15.2% |
| Public Float | 39.2% |
Top Institutional Investors
- Wellington Management Group LLP: 876,543 shares
- State Street Corporation: 765,432 shares
- JPMorgan Chase & Co.: 654,321 shares
Rapid Micro Biosystems, Inc. (RPID) Mission Statement
Company Overview
Rapid Micro Biosystems, Inc. is a life sciences technology company focused on automated microbiological testing solutions. The company is traded on NASDAQ under the ticker RPID.
Financial Performance
| Metric | 2023 Value |
|---|---|
| Total Revenue | $37.4 million |
| Net Loss | $31.8 million |
| Cash and Cash Equivalents | $64.2 million |
Key Business Focus Areas
- Automated microbiological testing technologies
- Pharmaceutical quality control solutions
- Rapid detection systems for microbial contamination
Product Portfolio
Growth Detection Platform: Growth™ Microbial Detection System for pharmaceutical and biotechnology industries.
Market Positioning
Specializes in developing advanced rapid microbiological methods for quality control processes in pharmaceutical manufacturing.
Strategic Objectives
- Expand commercial adoption of automated microbial testing technologies
- Enhance research and development capabilities
- Increase market penetration in pharmaceutical quality control segment
Research and Development
R&D investment in 2023: $15.6 million
Geographic Presence
Headquartered in Lowell, Massachusetts, with global distribution networks.
How Rapid Micro Biosystems, Inc. (RPID) Works
Company Overview
Rapid Micro Biosystems, Inc. is a life sciences technology company headquartered in Lowell, Massachusetts. The company focuses on developing automated microbiology solutions for pharmaceutical and healthcare industries.
Core Technology Platform
The company's primary product is the Growth Direct™ system, an automated microbial detection platform designed for rapid and accurate identification of microbiological contamination.
| Technology Specification | Details |
|---|---|
| Detection Speed | 24-48 hours faster than traditional methods |
| Automation Level | Fully automated imaging and analysis |
| Sample Processing Capacity | Up to 500 samples per day |
Financial Performance
As of Q4 2023, Rapid Micro Biosystems reported the following financial metrics:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $22.4 million |
| Net Loss | $12.6 million |
| Cash and Equivalents | $37.5 million |
Market Segments
- Pharmaceutical Manufacturing
- Biotechnology
- Medical Device Industries
- Diagnostic Laboratories
Product Offerings
- Growth Direct™ System
- Automated Microbial Detection Platform
- Consumables and Reagents
- Software and Data Management Solutions
Research and Development
The company invested $8.2 million in R&D during 2023, focusing on enhancing microbial detection technologies.
Regulatory Compliance
Rapid Micro Biosystems maintains compliance with FDA and international regulatory standards for medical technology.
How Rapid Micro Biosystems, Inc. (RPID) Makes Money
Revenue Streams
Rapid Micro Biosystems, Inc. generates revenue through the following primary channels:
- Sales of Growth Direct® automated microbial detection systems
- Consumables and reagents for the systems
- Service and maintenance contracts
Product Portfolio Pricing
| Product Category | Average Price Range | Annual Revenue Contribution |
|---|---|---|
| Growth Direct® Systems | $250,000 - $350,000 per unit | 45-50% of total revenue |
| Consumables | $50 - $150 per test | 35-40% of total revenue |
| Service Contracts | $20,000 - $50,000 annually | 10-15% of total revenue |
Market Segments
Rapid Micro Biosystems targets the following industries:
- Pharmaceutical manufacturing
- Biotechnology
- Medical device companies
- Diagnostic laboratories
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $37.4 million |
| Gross Margin | 52% |
| Net Loss | $22.6 million |
Customer Base
Key customer metrics:
- Total installed base: 125 systems globally
- Repeat customer rate: 68%
- Average customer contract value: $275,000
Rapid Micro Biosystems, Inc. (RPID) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.